Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review

Peer review reports

Original Submission
6 Aug 2020	Submitted	Original manuscript
5 Dec 2020	Reviewed	Reviewer Report - Magdalena Ratajska
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
2 Jan 2021	Editorially accepted
9 Jan 2021	Article published	10.1186/s13053-021-00165-2

Back to article page